Advertisement Fidelity
Home > Boards > Free Zone > Health and Sciences >

StocksDiva Bio Bin

RSS Feed
      Hide Sticky   Hide Intro
Moderator: StocksDiva Assistants:
Search This Board:
Last Post: 4/14/2014 8:40:17 AM - Followers: 134 - Board type: Free - Posts Today: 0


Be on the look out for companies developing drugs or biologics in research areas as cardiovascular disease, diseases of the central nervous system, autoimmune diseases, cancer, AIDS, diabetes, immunological diseases, infectious diseases, respiratory diseases, and so on where there is a high degree of  incidence in the population. Success in these areas will ensure the company a faster return on their investment in R&D and licensing efforts. You should also look out for drugs with orphan drug designation, which if approved gets seven years of marketing exclusivity.
 Biotechnology companies have become the major drivers of research in collaboration with pharmaceutical companies. A strong network of collaborative support is a strong indication that a company is financially and logically stable. Pharmaceutical companies can partner with a small biotech company and provide up-front dollars, followed by further investments as scientific milestones are achieved (e.g a regulatory submission, a successful completion of a key phase 2 study or an approval of a product). The small company usually gives up one of their lead products to the partner  or has a co-marketing agreement. 
Apart from full incorporation of one company into another, alliances between separate companies are a necessity for successful R&D (Research and Development). One company cannot have all the expertise and resources to cover all the basic science areas germaine to  their therapeutic areas of interest. Such that one company will have access to a particular added technology or product, which is shared through alliances and licensing deals. In 2003, over 800 such collaborations were signed for the pharma to biotech and the biotech to biotech agreements.
The financing of the industry involves a variety of sources of money needed to pay for the expensive and lengthy R&D , wherein the promise of a return (a new product) is far down the road, 5-10 years, from the first investment. The biotech segment of the pharmaceutical industry includes more than 4000 small companies worldwide with about 1500 of them in the USA and needs to employ a full range of financing to maintain their viability. It is estimated that usually 25% or more of biotech companies only have 2 years of financial capital left before they replenish their capital or go out of business. SO INVESTIGATE NEW COMPANIES CAREFULLY. It is important to consider where these companies get their funding and it can come from one of the sources listed:
  •  Partners- As mentioned above, big pharmaceutical companies can partner with a small biotech company and provide funding and further investment as scientific milestones are met.
  •  Debt-  A company can certainly go to banks and investment companies, creating debt by offering corporate bonds or taking on a loan of money, both of which pay interest to the lender, a bank or investor. The lender expects near term good news in product advancement and approval as their collateral for the loan.
  • PIPE (Private Investment in Public Equity)- this is a special funding by outside investors outside of the typical stock purchase.
  •  Venture Capital (VC)- This is often the first area of financing for a new company. The VC is a wealthy individual also known as "an angel" or a VC company. Venture Capital is provided usually in stages (up to seven) as the company advances its science and product development.
  • IPOs (initial public offering)- After a new company has progressed in their research with unique targets for disease mitigation or especially has products in a pipeline, they can go public and offer stock. Becoming a public company is a large source of income operations and it gives the company freedom to operate without the control or oversight of a partner.
  • follow-on- this is a later stock offering following an IPO. 
For any one company to move from a new start up company to marketing a product over the 10 years, they usually will need to employ a variety of these funding sources at different times. For publicly owned companies, you must judge whether they have excessively diluted their shares. Companies with private financing, milestone payments and sale of debt securities (secured and/or convertible) have more potential for stability than those without any of these sources.
Make sure you look for pipelines consisting of more than one product. Several criteria are important in establishing a successful and robust pipeline. Look out for product candidates in all four stages of development, a reasonable number of product candidates in all four stages of development, a reasonable, especially given that most will ultimately fail and not be carried forward, and  a reasonable number of candidates across important therapeutic areas such as cancer.
Companies that are highly valued but has gone through some tough times might be found at a lower price. The stock market is rough on companies that have hit a temporary bad news e.g a CRL, causing the price to over react. Prices might drop temporarily as a result of a slightly bad news, for example if the FDA gives a CRL due to a labeling issue that can easily be fixed in a few months. On the other hand, Prices could also drop permanently for a long time for example FDA gives a CRL requesting that additional clinical studies be conducted to show safety or efficacy. Small biotech companies also react to any slight good news as well, from new patent approval, to FDA "accept to file" decision on a marketing application and so on.
 A biotech company should be run by very knowledgeable entrepreneurs, and companies whose managers have a scientific background  or a strong research experience. These CEOs, COOs, CFOs, CSO,CMOs are all very much involved in the development of the company's products. 

    Look for products that are at the end of the FDA approval process, the bulk of testing has been completed on these products and the only thing the sponsor is waiting for is an approval decision to allow marketing of the product. Although by this stage, success is still not guaranteed because the FDA can deny approval for any reason even if the clinical results are perfect; They may sometimes have questions on manufacturing, labeling, and so on which could delay approval of the product.  


Motorbike Clip Art     Motorbike Clip Art


Example of a Time line on FDA approval stocks

Remember to always watch fda's and bio tech stocks very close, Keep track of the RSI...when it starts dropping...sell sell sell

    Time lines on FDA approval stocks generally has a very slim window of opportunity for making you profits.  I have gathered a time breakdown of data to show you how quickly they come into play and without delay go downward just as fast.  This particular stock opened the day at 9:30 am ET at .70 with only 300 in volume. She sat idle all trading day and as illustrated when the news hit at 2:59 pm ET, she took off like a house on fire.


    By 3:06 pm ET, word got around that she was approved and by 3:08 pm ET she peaked and by 3:09 pm ET, she started her downward slope.  Generally once BioTech stock with FDA approval starts her descent, you don't want to contemplate of whether to hold her, GET GREEN  and GET GONE!  Lesson learned or you might be waiting a long time for a companies pipeline to come around again. 

TIME and Sales to the end:

4:00 PM    1.07     220,854 3:31 PM    1.04     170,480 3:12 PM    1.30     137,912
3:59 PM    1.07     215,854 3:29 PM    1.00     170,362 3:11 PM    1.30     137,412
3:56 PM    1.07     214,854 3:24 PM    1.02     165,362 3:09 PM    1.425   135,712
3:54 PM    1.07     210,854 3:21 PM    1.04     154,412  
3:51 PM    1.02     210,654 3:19 PM    1.10     148,412 3:08 PM    1.50     129,022
3:49 PM    1.02     204,980 3:17 PM    1.02     143,292 3:07 PM    1.32     122,772
3:46 PM    1.02     199,980 3:16 PM    1.10     140,692


3:44 PM    1.02     187,480 3:14 PM    1.15     138,662 3:06 PM    1.25     120,372
3:42 PM    1.03     182,980 3:13 PM    1.25     138,412 3:04 PM    1.00     114,872
3:41 PM    1.03     181,480

Started back down

3:03 PM    1.08     97,572
3:40 PM    1.03     179,980   3:02 PM    1.01     591,522
3:35 PM    0.99     178,980   3:01 PM    0.74     54,060
3:32 PM    0.88     176,480   3:00 PM    0.70     29,526


NEWS that made it run fast & furious Ophthalmic Imaging Systems Receives FDA Clearance to Market Revolutionary New Portable Digital Imaging Device

November 30, 2009:


9:30 AM    0.70          300 (BEGINING OF TRADE DAY)




FDA Drug Approval Reports


How FDA works Power Point Presentation



~Always do you own DD~.  Good Luck and please add this board as your favorite

StocksDiva is not paid or compensated to report news and developments about publicly traded companies




Love them as much as they Love us....They are Coming HOME!!!

Thanks for the memories and the support...You all know who I am talking about:)

#11218  Sticky Note SPOM -SPO MEDICAL SYSTEMS due diligence StocksDiva 02/19/13 10:45:00 AM
#10996  Sticky Note BIO EARNINGS & CONFERENCES JAN-FEB/2013 StocksDiva 12/26/12 09:59:52 AM
#10991  Sticky Note FDA Calendar 12/26/12-03/17/13 StocksDiva 12/26/12 09:01:01 AM
#10088  Sticky Note FCSC/OTCBB. DD sheet. 2 impact-videos at the end. PoemStone 11/10/12 10:32:10 AM
#11421   BIND Therapeutics barasertib data positive, says JMP Securities StocksDiva 04/14/14 08:40:17 AM
#11420   CTIX Study Shows Cellceutix Antibiotic Active Against Drug-Resistant StocksDiva 04/14/14 08:39:11 AM
#11419   NBS NeoStem Announces Definitive Agreement to Acquire California StocksDiva 04/14/14 08:38:07 AM
#11418   ADXS Japan Patent Office Issues Advaxis a Notice StocksDiva 04/14/14 08:37:03 AM
#11417   PTLA Portola announces publication of Phase 3 APEX StocksDiva 04/14/14 08:35:52 AM
#11416   BMRN BioMarin says FDA extends Kuvan market exclusivity StocksDiva 04/14/14 08:34:59 AM
#11415   PLPL Extracts Could Further Shape Marijuana Debate StocksDiva 04/11/14 09:16:54 AM
#11414   NVLX Engages ViruSure to Establish Cell Banks for StocksDiva 04/10/14 09:10:08 AM
#11413   OMED - OncoMed Presents Data on Multiple Anti-Cancer StocksDiva 04/08/14 09:41:22 AM
#11412   HALO - Halozyme Announces Preclinical Data Presentations At StocksDiva 04/08/14 09:40:32 AM
#11411   HEB - Hemispherx Biopharma Announces New Publication Enlarges StocksDiva 04/08/14 09:39:48 AM
#11410   NVLX - Medical Marijuana Sciences' Dr. Mark L. StocksDiva 04/08/14 09:18:26 AM
#11409   PLPL Qualifies for Grant From South African Department StocksDiva 04/08/14 09:02:37 AM
#11408   Please say a prayer for me today... Stitches StocksDiva 04/07/14 07:12:56 AM
#11407   Awesome! she smiled... She is home and recovering StocksDiva 04/03/14 09:10:37 AM
#11406   Prayers for a speedy, complete recovery! rayinbrooklyn65 04/03/14 07:05:32 AM
#11405   This might help her recovery a little bit.. $UPERMAN 04/02/14 10:27:27 PM
#11404   give mom my very best!!!!!!!! malamute 04/01/14 07:26:38 AM
#11403   StocksDiva - Mom update: She is out of StocksDiva 03/30/14 11:53:39 AM
#11402   remember me ?????? malamute 03/20/14 03:28:56 PM
#11401   PLPL Announces Favorable Results for Human Clinical Trial StocksDiva 03/20/14 09:35:27 AM
#11400   NVLX Contracts With Austrianova for cGMP-Compliant Cell-in-a-Box(R) Encapsulatio StocksDiva 03/20/14 09:09:04 AM
#11399   Cool PLPL Video of the test Stage 1 StocksDiva 03/19/14 09:44:10 AM
#11398   PLPL Completes Stage 1 of Senteeko Phytofare Factory, StocksDiva 03/18/14 11:55:03 AM
#11397   PLPL is one of the few cannabis OTC StocksDiva 03/18/14 08:09:59 AM
#11396   MDVN Astellas and Medivation Submit Supplemental New Drug StocksDiva 03/18/14 07:42:07 AM
#11395   ADXS Advaxis Receives Patent in Japan for ADXS-HPV StocksDiva 03/18/14 07:41:28 AM
#11394   BIIB Biogen Idec Receives Notification of PDUFA Date StocksDiva 03/18/14 07:40:48 AM
#11393   The NVLX presentation entitled "Cell-in-a-Box® Living Cell Encapsulation StocksDiva 03/18/14 07:34:30 AM
#11392   ty ty, gave you a personal mark. StocksDiva 03/17/14 07:44:06 PM
#11391   StocksDiva..appreciate your posts. Seen your posts on trademax42 03/17/14 06:33:42 PM
#11390   NVLX Professor Dr. Walter H. Gunzburg, Executive Chairman StocksDiva 03/17/14 10:41:27 AM
#11389   Achillion Pharmaceuticals, Inc. (ACHN) today announced that two StocksDiva 03/14/14 08:52:27 AM
#11388   Idenix Pharmaceuticals, Inc. (IDIX),announced that it has filed StocksDiva 03/14/14 08:51:12 AM
#11387   NVLX Nuvilex Appoints CEO and President of Austrianova StocksDiva 03/11/14 09:09:19 AM
#11386   Global Links Corp. (GLCO), today announced that the StocksDiva 03/11/14 08:38:58 AM
#11385   PPHM Data Presentations at Keystone Symposium Support Potential StocksDiva 03/11/14 08:26:10 AM
#11384   RNN Rexahn Announces Initial Results from Phase I StocksDiva 03/11/14 08:24:55 AM
#11383   SNTA Synta and QuantumLeap Healthcare Collaborative Announce Selection StocksDiva 03/11/14 07:37:20 AM
#11382   AMGN -Bayer and Onyx Report Phase 3 Study StocksDiva 03/11/14 07:36:09 AM
#11381   LJPC La Jolla Pharmaceutical Shares Surge on Positive StocksDiva 03/11/14 07:34:25 AM
#11380   PLPL Plandai Assumes Role in Legalizing Medical Marijuana StocksDiva 03/11/14 07:11:33 AM
#11379   PLPL now owns 100% of Dunn Roman Holdings StocksDiva 03/10/14 09:55:35 AM
#11378   found this article on NVLX - Nuvilex appointed StocksDiva 03/10/14 09:54:31 AM
#11377   Mid day News! PLPL Announces Acquisition of Minority StocksDiva 03/07/14 12:30:51 PM
#11376   PLPL former Microsoft executive Jamen Shively has been StocksDiva 03/07/14 09:36:53 AM
#11375   NVLX up 2.51 on extended trade, Looks like lastcall59 03/07/14 09:25:42 AM
#11374   NVLX Nuvilex Appoints Dr. Garret L. Yount to StocksDiva 03/07/14 09:03:55 AM
#11373   INCY Incyte Announces Positive Top-Line Results from Phase StocksDiva 03/07/14 08:28:18 AM
#11372   EBS VALNEVA Announces a New Research Agreement and StocksDiva 03/07/14 08:24:19 AM